ADRs End Lower, Purple Biotech Ltd. Declines 29%
This article was automatically generated by Dow Jones Newswires using technology from Automated Insights.
International stocks trading in New York closed lower on Tuesday as the S&P/BNY Mellon index of American depositary receipts fell 0.9% to 172.61.
The European index declined 0.6% to 167.71. The Asian index fell 1.2% to 201.48. The Latin American index lost 1.8% to 203.39, while the emerging-markets index dropped 0.9% to 320.34.
Purple Biotech Ltd., based in Israel, posted the largest decline, cratering 29% to 41 cents, followed by shares of China's Cheetah Mobile Inc., which tumbled 20% to $3.89. Shares of Australia-based Alterity Therapeutics Ltd. plunged 16% to $2.05.
Hong Kong's Lion Group Holding Ltd. was the biggest leader during the session, surging 11% to 77 cents. Japan-based Pixie Dust Technologies Inc. rose 9.7% to $2.60. Argo Blockchain PLC, which is based in the U.K., rounded out the top three leaders on Tuesday, with shares rising 7.5% to $1.44.
Data source: Dow Jones Market Data, FactSet.
(END) Dow Jones Newswires
April 16, 2024 17:04 ET (21:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track